Parexel posts double-digit Q1 sales, earnings jump
Parexel International Inc. (NSDQ:PRXL) posted profits of $17.8 million, or 30 cents per diluted share, on sales of $342.3 million during the three months ended Sept. 30. That compares with profits of $12.4 million, or 21 cents per diluted share, on sales of $307.5 million during the same period last year.
Read more
AthroCare’s top-line boost pushes it to Q3 profits
ArthroCare Corp. (NSDQ:ATRC) posted profits of $9.3 million, or 25 cents per diluted share, on sales of $87.9 million during the three months ended Sept. 30. That compares with a net loss of $4.4 million, or $1.18 per diluted share, on sales of $79.5 million during the same period last year.
Read more
Span-America’s Q4 sales, earnings slide
Span-America Medical Systems Inc. (NSDQ:SPAN) posted net income of $1.2 million, or 42 cents per diluted share, on sales of $13.8 million during the three months ended Oct. 2. That compares with profits of $1.6 million, or 57 cents per diluted share, on sales of $14.8 million during the same period last year.
Read more
Allergan’s sales rise as it swings to a Q3 loss
Allergan Inc. (NYSE:AGN) posted net losses of $671 million, or $2.21 per diluted share, on sales of $1.21 billion during the three months ended Sept. 30. That compares with profits of $179 million, or 58 cents per diluted share, on sales of $1.14 billion during the same period last year.
Read more
Alere’s revenues edge up, but bottom line shrinks
Alere Inc. (NSDQ:ALR) reported profits of $61.3 million, or 59 cents per diluted share, on sales of $534.6 million during the three months ended Sept. 30. That compares with profits of $72.6 million, or 74 cents per diluted share, on sales of $504.8 million during the same period last year.
Read more
Stereotaxis trims losses, but remains in the red
Stereotaxis Inc. (NSDQ:STXS) recorded a loss of $5.1 million, or 10 cents per diluted share, on revenue of $13.9 million during the three months ended Sept. 30. That compares with a loss of $5.8 million, or 14 cents per diluted share, on sales of $13.3 million during the same period last year.
Read more
